skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Histologic progression in non-hodgkin's lymphoma

Abstract

The clinical course and biopsy specimens from 515 consecutive non-Hodgkin's lymphoma patients was evaluated retrospectively in an attempt to determine the clinical importance of documented changes in histology over time. Two-hundred and five of these patients has an initial diagnosis of nodular lymphoma and were reviewed for this anaysis. Sixty-three underwent a repeat biopsy greater than 6 mo after initial diagnosis. In 23 patients, these repeat biopsies revealed a change in histology to a diffuse pattern and/or a change to a larger ''histiocytic'' cell type, while repeat biopsies for the other 40 (63%) disclosd persistence of a nodular pattern and no clear change in basic cell type. Progression from nodular lymphoma to diffuse histiocytic, mixed, or undifferentiated types of lymphomas of Rappaport was found in repeate biopsies obtained from 19 patients (30%). Prognosis for survival following a biopsy that demonstrated histologic change was related to the histology demonstrated at the most recent biopsy and to the response to subsequent drug treatment. Survival following repeat biopsy for these 19 patients was significantly shorter than for the 40 patients whose histology remained nodular (p < 0.001). However, attainment of a complete remission with intensive combination chemotherapy was associated with prolonged survival inmore » eight patients and prolonged disease-free survival in one patient. Since prior treatment may compromise the ability to achieve a complete response to chemotherapy in patients with nodular lymphoma who develop an aggressive diffuse histology, the likelihood of histologic progression must be considered in the design of future clinical trials in nodular lymphoma. Histologic progression does not preclude attainment of a complete response to intensive chemotherapy.« less

Authors:
 [1]; ; ; ; ; ; ; ; ;
  1. National Cancer Inst., Bethesda, MD
Publication Date:
OSTI Identifier:
5636704
Resource Type:
Journal Article
Journal Name:
Blood; (United States)
Additional Journal Information:
Journal Volume: 59:2
Country of Publication:
United States
Language:
English
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; LYMPHOMAS; BIOLOGICAL RADIATION EFFECTS; RADIOTHERAPY; SIDE EFFECTS; BIOPSY; CHEMOTHERAPY; HISTOLOGY; MUTAGENESIS; PATIENTS; SURVIVAL TIME; BIOLOGICAL EFFECTS; DIAGNOSTIC TECHNIQUES; DISEASES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIATION EFFECTS; RADIOLOGY; THERAPY; 560151* - Radiation Effects on Animals- Man

Citation Formats

Hubbard, S M, Chabner, B A, DeVita, Jr, V T, Simon, R, Berard, C W, Jones, R B, Garvin, A J, Canellos, G P, Osborne, C K, and Young, R C. Histologic progression in non-hodgkin's lymphoma. United States: N. p., 1982. Web.
Hubbard, S M, Chabner, B A, DeVita, Jr, V T, Simon, R, Berard, C W, Jones, R B, Garvin, A J, Canellos, G P, Osborne, C K, & Young, R C. Histologic progression in non-hodgkin's lymphoma. United States.
Hubbard, S M, Chabner, B A, DeVita, Jr, V T, Simon, R, Berard, C W, Jones, R B, Garvin, A J, Canellos, G P, Osborne, C K, and Young, R C. 1982. "Histologic progression in non-hodgkin's lymphoma". United States.
@article{osti_5636704,
title = {Histologic progression in non-hodgkin's lymphoma},
author = {Hubbard, S M and Chabner, B A and DeVita, Jr, V T and Simon, R and Berard, C W and Jones, R B and Garvin, A J and Canellos, G P and Osborne, C K and Young, R C},
abstractNote = {The clinical course and biopsy specimens from 515 consecutive non-Hodgkin's lymphoma patients was evaluated retrospectively in an attempt to determine the clinical importance of documented changes in histology over time. Two-hundred and five of these patients has an initial diagnosis of nodular lymphoma and were reviewed for this anaysis. Sixty-three underwent a repeat biopsy greater than 6 mo after initial diagnosis. In 23 patients, these repeat biopsies revealed a change in histology to a diffuse pattern and/or a change to a larger ''histiocytic'' cell type, while repeat biopsies for the other 40 (63%) disclosd persistence of a nodular pattern and no clear change in basic cell type. Progression from nodular lymphoma to diffuse histiocytic, mixed, or undifferentiated types of lymphomas of Rappaport was found in repeate biopsies obtained from 19 patients (30%). Prognosis for survival following a biopsy that demonstrated histologic change was related to the histology demonstrated at the most recent biopsy and to the response to subsequent drug treatment. Survival following repeat biopsy for these 19 patients was significantly shorter than for the 40 patients whose histology remained nodular (p < 0.001). However, attainment of a complete remission with intensive combination chemotherapy was associated with prolonged survival in eight patients and prolonged disease-free survival in one patient. Since prior treatment may compromise the ability to achieve a complete response to chemotherapy in patients with nodular lymphoma who develop an aggressive diffuse histology, the likelihood of histologic progression must be considered in the design of future clinical trials in nodular lymphoma. Histologic progression does not preclude attainment of a complete response to intensive chemotherapy.},
doi = {},
url = {https://www.osti.gov/biblio/5636704}, journal = {Blood; (United States)},
number = ,
volume = 59:2,
place = {United States},
year = {Mon Feb 01 00:00:00 EST 1982},
month = {Mon Feb 01 00:00:00 EST 1982}
}